NeoGenomics to Announce First Quarter 2023 Financial Results
NeoGenomics, Inc. (NASDAQ:NEO) announced that it will release its first quarter 2023 financial results on May 8, 2023, followed by a webcast and conference call at 4:30 p.m. Eastern Time. Interested investors can join the call via telephone or access it through the company's Investor Relations website. The company specializes in cancer genetics testing and offers a wide range of oncology-focused testing services. NeoGenomics operates CAP accredited and CLIA certified laboratories across the United States and internationally, serving a diverse clientele in the oncology field. This upcoming financial announcement is crucial for investors tracking the company's performance and strategic initiatives.
- None.
- None.
FT. MYERS, FL / ACCESSWIRE / April 17, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that it will release its first quarter 2023 financial results on Monday, May 8, 2023. Along with the release, NeoGenomics will host a webcast and conference call that day at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
To access the live call via telephone, interested investors should dial (888) 506-0062 (domestic) and (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 357448.
The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to all relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to ensure the data we maintain is secured at all times.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Cambridge, United Kingdom; Rolle, Switzerland; and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.
For further information, please contact:
NeoGenomics, Inc.
Kendra Sweeney
Vice President, Investor Relations and Communications
Kendra.sweeney@neogenomics.com
T: +1-239-877-7474
SOURCE: NeoGenomics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/749298/NeoGenomics-to-Announce-First-Quarter-2023-Financial-Results
FAQ
When will NeoGenomics release its first quarter 2023 financial results?
What time is the NeoGenomics conference call for the financial results?
How can investors access the NeoGenomics financial results call?
What services does NeoGenomics provide?
